Autobahn Therapeutics completes $100 million Series C financing led by Newpath Partners to advance novel therapeutics for depression and other CNS disorders.
Autobahn Therapeutics completes $100 million Series C financing led by Newpath Partners to advance novel therapeutics for depression and other CNS disorders.
07/24/24, 11:34 AM
Location
san diegoMoney raised
$100 million
Industry
therapeutics
biotechnology
health care
Round Type
series c
Investors
Gt Healthcare Capital Partners, Alexandria Venture Investments, Section 32, Pfizer Ventures, Bristol Myers Squibb, Biogen, Samsara Bio Capital, Invus, Bvf Partners, Blue Owl Healthcare Opportunities, Arch Venture Partners, Insight Partners, Monograph Capital, Canaan Partners, Newpath Partners
Autobahn Therapeutics, a biotechnology company, has closed an oversubscribed $100 million Series C financing round. The funding was led by Newpath Partners, with participation from new investors Canaan Partners, Monograph Capital, and Insight Partners, as well as existing investors.
Company Info
Location
san diego, california, united states
Additional Info
Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Leveraging its proprietary brain-targeting chemistry platform, Autobahn aims to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist, being developed initially for people with treatment-resistant depression. Autobahn Therapeutics is based in San Diego.